Stockscreener 앱 받기
0.8344
7.29%
-0.0656
시간 외 거래:
.87
0.0356
+4.27%
전일 마감가:
$0.90
열려 있는:
$0.94
하루 거래량:
134.29K
Relative Volume:
0.45
시가총액:
$14.90M
수익:
-
순이익/손실:
$-11.24M
주가수익비율:
-1.0957
EPS:
-0.7615
순현금흐름:
$-4.79M
1주 성능:
-21.28%
1개월 성능:
-10.28%
6개월 성능:
-27.44%
1년 성능:
-18.20%
1일 변동 폭
$0.8065
$0.94
1주일 범위
$0.8065
$1.05
52주 변동 폭
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
MIRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.8344 | 14.90M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
738.21 | 680.03B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
186.96 | 346.93B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
153.24 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
62.55 | 286.54B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
105.85 | 213.57B | 51.72B | 11.94B | 13.81B | 5.88 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
Equities Analysts Issue Forecasts for MIRA FY2026 Earnings - Defense World
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment - Investing.com Australia
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment By Investing.com - Investing.com Philippines
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain - ACCESS Newswire
Game-Changing Pain Treatment Enters Clinical Trials: Superior to Current Options in Early Data - Stock Titan
Mira Pharmaceuticals IncEnrolls First Subjects In Phase 1 Trial For Ketamir-2SEC Filing - MarketScreener
63,410 Shares in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Purchased by Virtu Financial LLC - Defense World
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March - Defense World
MIRA Pharmaceuticals (MIRA) Expected to Announce Earnings on Monday - Defense World
MIRA Pharmaceuticals Inc. (MIRA) reports earnings - Quartz
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened - Defense World
MIRA bids for SKNY - The Pharma Letter
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals - MSN
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy - Investing.com
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal - Investing.com India
Mira Pharmaceuticals Inc To Acquire Skny PharmaceuticalsSEC Filing -March 24, 2025 at 08:02 am EDT - MarketScreener
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - Benzinga
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development - ACCESS Newswire
Major Pharma Deal: MIRA's $5M Backed Entry Into $150B Weight Loss Market - Stock Titan
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Yahoo Finance
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead
Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - Yahoo Finance
Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com
Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com
Mira Pharmaceuticals expands pain management pipeline - Investing.com India
Mira Pharmaceuticals expands Ketamir-2 development with topical treatment - TipRanks
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Weatherford Democrat
Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga
What is Zacks Small Cap’s Estimate for MIRA FY2024 Earnings? - Armenian Reporter
What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World
Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia
SponsoredImpartialComprehensive - Research Tree
Urgent Boots paracetamol recall after packets found to contain a different drug - AOL
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com
Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com
Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com
Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India
Tiziana stock jumps 12% on TBI drug study publication - MSN
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL
Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters
MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha
Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater
Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater
Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater
Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.83%
자본화:
|
볼륨(24시간):